Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Inventory (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Inventory for 4 consecutive years, with $27.9 million as the latest value for Q4 2025.

  • Quarterly Inventory rose 77.59% to $27.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27.9 million through Dec 2025, up 77.59% year-over-year, with the annual reading at $27.9 million for FY2025, 77.59% up from the prior year.
  • Inventory hit $27.9 million in Q4 2025 for Axsome Therapeutics, up from $23.8 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $27.9 million in Q4 2025 to a low of $2.1 million in Q3 2022.
  • Historically, Inventory has averaged $13.8 million across 4 years, with a median of $15.1 million in 2023.
  • Biggest YoY gain for Inventory was 374.69% in 2023; the steepest drop was 10.38% in 2023.
  • Year by year, Inventory stood at $4.3 million in 2022, then soared by 250.35% to $15.1 million in 2023, then rose by 3.94% to $15.7 million in 2024, then surged by 77.59% to $27.9 million in 2025.
  • Business Quant data shows Inventory for AXSM at $27.9 million in Q4 2025, $23.8 million in Q3 2025, and $18.4 million in Q2 2025.